Genetic Determinants of Opioids Analgesia - Tabular View

Tracking Information

First Received Date ^ICMJE

September 12, 2005

Last Updated Date

October 28, 2008

Start Date ^ICMJE

August 1997

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Total alfentanil dose used during the procedure.
The extent of respiratory depression.

Original Primary Outcome Measures ^ICMJE

1. Total alfentanil dose used during the procedure
2. The extent of respiratory depression

Change History

Complete list of historical versions of study NCT00226564 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Genetic Determinants of Opioids Analgesia

Official Title ^ICMJE

The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy

Brief Summary

The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors.

The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.

Detailed Description

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Condition ^ICMJE

Nephrolithiasis

Intervention ^ICMJE

Drug: Alfentanil

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

100

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Age > 20

Exclusion Criteria:

Regular use of opioid drugs
Known hypersensitivity to alfentanil

Gender

Both

Ages

20 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Israel

Administrative Information

NCT ID ^ICMJE

NCT00226564

Responsible Party

Study ID Numbers ^ICMJE

yc19554-HMO-CTIL

Study Sponsor ^ICMJE

Hadassah Medical Organization

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Yoseph Caraco, MD

Hadassah Medical Organization, Jerusalem, Israel

Information Provided By

Hadassah Medical Organization

Verification Date

October 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP